Rheumatoid arthritis drug market will grow to $18.2 billion in 2023, report

17 September 2014

The rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion in 2013 to over $18.2 billion in 2023 in the USA, France, Germany, Italy, Spain, the UK and Japan, new research has forecast.

According to a new report from Decision Resources Group, TNF-alpha inhibitors will remain the leading drug class in both sales and patient shares in the RA market, but growth will be constrained and patient shares will decline due to the uptake of oral Janus kinase (Jak) inhibitors and the entry of alternative biological agents.

In particular, the growth of the Jak inhibitor drug class, driven by the anticipated approval of Pfizer's (NYSE: PFE) tofacitinib (Xeljanz) in Europe and two emerging drugs - Eli Lilly (NYSE: LLY)/Incyte's '(Nasdaq: INCY) baricitinib and Vertex's (Nasdaq: VRTX) VX-509 - will be the major contributor to the growth of the RA market from 2013 to 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK